Andreas Engert
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin C, Kobe C. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC cancer 2022; 22:672.
Jun 18, 2022Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
Jun 18, 2022BMC cancer 2022; 22:672
van Heek Lutz, Stuka Colin, Kaul Helen, Müller Horst, Mettler Jasmin, Hitz Felicitas, Baues Christian, Fuchs Michael, Borchmann Peter, Engert Andreas, Dietlein Markus, Voltin Conrad-Amadeus, Kobe Carsten
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Kreissl S, Keller U, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Bentz M, Hitz F, Topp M, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021; 8:e398-e409.
Jun 1, 2021PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Jun 1, 2021Lancet Haematol 2021; 8:e398-e409
Kreissl Stefanie, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Diehl Volker, Dietlein Markus, Engert Andreas, Borchmann Peter, Bentz Martin, Hitz Felicitas, Topp Max S, Goergen Helen, Buehnen Ina, Kobe Carsten, Moccia Alden, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, German Hodgkin Study Group
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
Hartmann S, Hansmann M, Engert A, Rosenwald A, Möller P, Klapper W, Stein H, Quintanilla-Martinez L, Fend F, Cogliatti S, Ott G, Feller A, Bernd H, Mottok A, Plütschow A, Eichenauer D. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. Am J Hematol 2019; 94:1208-1213.
Aug 21, 2019The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
Aug 21, 2019Am J Hematol 2019; 94:1208-1213
Hartmann Sylvia, Hansmann Martin-Leo, Engert Andreas, Rosenwald Andreas, Möller Peter, Klapper Wolfram, Stein Harald, Quintanilla-Martinez Leticia, Fend Falko, Cogliatti Sergio B., Ott German, Feller Alfred C, Bernd Heinz-Wolfram, Mottok Anja, Plütschow Annette, Eichenauer Dennis A
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390:2790-2802.
Oct 20, 2017PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Oct 20, 2017Lancet 2017; 390:2790-2802
Borchmann Peter, Bentz Martin, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Schmitz Norbert, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Kuhnert Georg, Diehl Volker, Dietlein Markus, Hitz Felicitas, Topp Max S, Goergen Helen, Kobe Carsten, Lohri Andreas, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Hüttmann Andreas, Dierlamm Judith, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, Engert Andreas
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
Kreissl S, Borchmann P, Engert A, Diehl V, Fuchs M, Flechtner H, Rueffer J, Shonukan O, Soekler M, Hitz F, Halbsguth T, Behringer K, Brillant C, Mayer A, Goergen H, Mueller H. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol 2016; 17:1453-1462.
Sep 6, 2016Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
Sep 6, 2016Lancet Oncol 2016; 17:1453-1462
Kreissl Stefanie, Borchmann Peter, Engert Andreas, Diehl Volker, Fuchs Michael, Flechtner Hans-Henning, Rueffer Jens Ulrich, Shonukan Oluwatoyin, Soekler Martin, Hitz Felicitas, Halbsguth Teresa Veronika, Behringer Karolin, Brillant Corinne, Mayer Axel, Goergen Helen, Mueller Horst
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Böll B, Engert A, Diehl V, Fuchs M, Borchmann S, Bürkle C, Eichenauer D, von Tresckow B, Greil R, Kerkhoff A, Hitz F, Bröckelmann P, Behringer K, Goergen H, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127:2189-92.
Feb 1, 2016Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Feb 1, 2016Blood 2016; 127:2189-92
Böll Boris, Engert Andreas, Diehl Volker, Fuchs Michael, Borchmann Sven, Bürkle Carolin, Eichenauer Dennis A, von Tresckow Bastian, Greil Richard, Kerkhoff Andrea, Hitz Felicitas, Bröckelmann Paul J, Behringer Karolin, Goergen Helen, Borchmann Peter
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Behringer K, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause S, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, Bentz M, Vieler T, Kriz J, Goergen H, Tanner A, Zijlstra J, Greil R, Markova J, Sasse S, Fuchs M, Topp M, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2014; 385:1418-27.
Dec 22, 2014Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Dec 22, 2014Lancet 2014; 385:1418-27
Behringer Karolin, Lange Elisabeth, Mahlberg Rolf, Hassler Andre, Vogelhuber Martin, Hahn Dennis, Mezger Jörg, Krause Stefan W, Skoetz Nicole, Böll Boris, von Tresckow Bastian, Diehl Volker, Hallek Michael, Borchmann Peter, Stein Harald, Eich Hans, Engert Andreas, Bentz Martin, Vieler Tom, Kriz Jan, Goergen Helen, Tanner Antonia, Zijlstra Josée M, Greil Richard, Markova Jana, Sasse Stephanie, Fuchs Michael, Topp Max S, Soekler Martin, Mathas Stephan, Meissner Julia, Wilhelm Martin, Koch Peter, Lindemann Hans-Walter, Schalk Enrico, Semrau Robert
Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG)
Hartmann S, Engert A, Hansmann M, Stein H, Rosenwald A, Möller P, Ott G, Feller A, Hummel M, Cogliatti S, Bernd H, Koch K, Bob R, Mottok A, Plütschow A, Eichenauer D, Klapper W. Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG). Br J Haematol 2014; 167:238-42.
Jun 26, 2014Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG)
Jun 26, 2014Br J Haematol 2014; 167:238-42
Hartmann Sylvia, Engert Andreas, Hansmann Martin-Leo, Stein Harald, Rosenwald Andreas, Möller Peter, Ott German, Feller Alfred C, Hummel Michael, Cogliatti Sergio B., Bernd Heinz-Wolfram, Koch Karoline, Bob Roshanak, Mottok Anja, Plütschow Annette, Eichenauer Dennis A, Klapper Wolfram
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
Hartmann S, Engert A, Hansmann M, Stein H, Rosenwald A, Möller P, Ott G, Feller A, Hummel M, Cogliatti S, Bernd H, Koch K, Bob R, Mottok A, Plütschow A, Eichenauer D, Klapper W. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013; 122:4246-52; quiz 4292.
Oct 7, 2013The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
Oct 7, 2013Blood 2013; 122:4246-52; quiz 4292
Hartmann Sylvia, Engert Andreas, Hansmann Martin-Leo, Stein Harald, Rosenwald Andreas, Möller Peter, Ott German, Feller Alfred C, Hummel Michael, Cogliatti Sergio B., Bernd Heinz-Wolfram, Koch Karoline, Bob Roshanak, Mottok Anja, Plütschow Annette, Eichenauer Dennis A, Klapper Wolfram
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Borchmann P, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause S, Mueller R, Fuchs M, Rank A, Greil R, Haverkamp H, Diehl V, Cerny T, Markova J, Ho A, Eich H, Mueller-Hermelink H, Kanz L, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29:4234-42.
Oct 11, 2011Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Oct 11, 2011J Clin Oncol 2011; 29:4234-42
Borchmann Peter, Paulus Ursula, Smardova Lenka, Huber Christoph, Dörken Bernd, Nerl Christoph, Krause Stefan W, Mueller Rolf-Peter, Fuchs Michael, Rank Andreas, Greil Richard, Haverkamp Heinz, Diehl Volker, Cerny Thomas, Markova Jana, Ho Anthony D, Eich Hans-Theodor, Mueller-Hermelink Hans Konrad, Kanz Lothar, Engert Andreas
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Schulz H, Engert A, Diehl V, Schnell R, Borchmann P, Rüdiger T, Driessen C, Elter T, Morschhauser F, Rehwald U, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109-11.
Jan 1, 2008Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Jan 1, 2008Blood 2008; 111:109-11
Schulz Holger, Engert Andreas, Diehl Volker, Schnell Roland, Borchmann Peter, Rüdiger Thomas, Driessen Christoph, Elter Thomas, Morschhauser Franck, Rehwald Ute, Reiser Marcel
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Rehwald U, Engert A, Diehl V, Muller-Hermelink K, Rüdiger T, Driessen C, Morschhauser F, Staak J, Sieber M, Reiser M, Schulz H, German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101:420-4.
Jan 15, 2003Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Jan 15, 2003Blood 2003; 101:420-4
Rehwald Ute, Engert Andreas, Diehl Volker, Muller-Hermelink Konrad, Rüdiger Thomas, Driessen Christoph, Morschhauser Franck, Staak Jan Oliver, Sieber Markus, Reiser Marcel, Schulz Holger, German Hodgkin Lymphoma Study Group (GHSG)